{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:56:25Z","timestamp":1779256585952,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00198-019-05127-y","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T17:10:46Z","timestamp":1571850646000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-7121","authenticated-orcid":false,"given":"W.-Y.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.-S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-S.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"5127_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4158\/EP161678.RA","volume":"23","author":"SG Albert","year":"2017","unstructured":"Albert SG, Reddy S (2017) Clinical evaluation of cost efficacy of drugs for treatment of osteoporosis: a meta-analysis. Endocr Pract 23:841\u2013856","journal-title":"Endocr Pract"},{"key":"5127_CR2","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, Drake MT, Mullan RJ et al (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871\u20131880","journal-title":"J Clin Endocrinol Metab"},{"key":"5127_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"5127_CR4","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of O, Maxillofacial S (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"5127_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"5127_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B (2016) The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85:142\u2013147","journal-title":"Bone"},{"key":"5127_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","volume":"140","author":"PP Sedghizadeh","year":"2009","unstructured":"Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF (2009) Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. an institutional inquiry. J Am Dent Assoc 140:61\u201366","journal-title":"an institutional inquiry. J Am Dent Assoc"},{"key":"5127_CR8","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1210\/jc.2013-4119","volume":"99","author":"WY Chiu","year":"2014","unstructured":"Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS (2014) The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab 99:2729\u20132735","journal-title":"J Clin Endocrinol Metab"},{"key":"5127_CR9","doi-asserted-by":"publisher","first-page":"e0196419","DOI":"10.1371\/journal.pone.0196419","volume":"13","author":"WY Chiu","year":"2018","unstructured":"Chiu WY, Yang WS, Chien JY, Lee JJ, Tsai KS (2018) The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PloS one 13:e0196419","journal-title":"PloS one"},{"key":"5127_CR10","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1210\/jc.2004-1750","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J (2005) Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 90:5018\u20135024","journal-title":"J Clin Endocrinol Metab"},{"key":"5127_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10928-015-9432-2","volume":"42","author":"W Denney","year":"2015","unstructured":"Denney W, Duvvuri S, Buckeridge C (2015) Simple, automatic noncompartmental analysis: the PKNCA R package. Journal of Pharmacokinetics and Pharmacodynamics 42:11\u2013107 S165","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"5127_CR12","first-page":"1","volume-title":"Textbook of therapeutics: drug and disease management, Eighth edn","author":"B Meibohm","year":"2006","unstructured":"Meibohm B, Evans WE (2006) Clinical pharmacodynamics and pharmacokinetics. In: Helms RA (ed) Textbook of therapeutics: drug and disease management, Eighth edn. Lippincott Williams and Wilkins, Philadelphia, pp 1\u201330"},{"key":"5127_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/10543409708835177","volume":"7","author":"LF Lacey","year":"1997","unstructured":"Lacey LF, Keene ON, Pritchard JF, Bye A (1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat 7:171\u2013178","journal-title":"J Biopharm Stat"},{"key":"5127_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/019262339502300203","volume":"23","author":"LZ Benet","year":"1995","unstructured":"Benet LZ, Zia-Amirhosseini P (1995) Basic principles of pharmacokinetics. Toxicol Pathol 23:115\u2013123","journal-title":"Toxicol Pathol"},{"key":"5127_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","volume":"15","author":"F Bauss","year":"2004","unstructured":"Bauss F, Russell RG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423\u2013433","journal-title":"Osteoporos Int"},{"key":"5127_CR16","first-page":"289","volume":"70","author":"F Bauss","year":"2002","unstructured":"Bauss F, Endele R, Besenfelder E, Hoelck JP (2002) Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection. Calcified Tissue Internation 70:289\u2013290 [Abstract P-128","journal-title":"Calcified Tissue Internation"},{"key":"5127_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","volume":"6","author":"RC Muhlbauer","year":"1991","unstructured":"Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H (1991) BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003\u20131011","journal-title":"J Bone Miner Res"},{"key":"5127_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barrett","year":"2004","unstructured":"Barrett J, Worth E, Bauss F, Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. Journal of clinical pharmacology 44:951\u2013965","journal-title":"Journal of clinical pharmacology"},{"key":"5127_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385","journal-title":"Bone"},{"key":"5127_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S (2011) Pharmacology of bisphosphonates. Bone 49:42\u201349","journal-title":"Bone"},{"key":"5127_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bone.2005.05.007","volume":"37","author":"S Epstein","year":"2005","unstructured":"Epstein S, Zaidi M (2005) Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 37:433\u2013440","journal-title":"Bone"},{"key":"5127_CR22","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN (2011) Clinical pharmacokinetics and pharmacodynamics: concepts and applications. Wolters Kluwer Health\/Lippincott William & Wilkins, Philadelphia"},{"key":"5127_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315\u2013328","journal-title":"Clin Pharmacokinet"},{"key":"5127_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/0006-2952(93)90328-T","volume":"46","author":"X Boulenc","year":"1993","unstructured":"Boulenc X, Marti E, Joyeux H, Roques C, Berger Y, Fabre G (1993) Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochemical pharmacology 46:1591\u20131600","journal-title":"Biochemical pharmacology"},{"key":"5127_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/jps.2600830521","volume":"83","author":"IM Twiss","year":"1994","unstructured":"Twiss IM, de Water R, den Hartigh J, Sparidans R, Ramp-Koopmanschap W, Brill H, Wijdeveld M, Vermeij P (1994) Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. Journal of pharmaceutical sciences 83:699\u2013703","journal-title":"Journal of pharmaceutical sciences"},{"key":"5127_CR26","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/jps.2600831218","volume":"83","author":"JH Lin","year":"1994","unstructured":"Lin JH, Chen IW, deLuna FA (1994) On the absorption of alendronate in rats. Journal of pharmaceutical sciences 83:1741\u20131746","journal-title":"Journal of pharmaceutical sciences"},{"key":"5127_CR27","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1210\/jc.2012-1027","volume":"97","author":"S Khosla","year":"2012","unstructured":"Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97:2272\u20132282","journal-title":"J Clin Endocrinol Metab"},{"key":"5127_CR28","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13318-014-0242-5","volume":"41","author":"K Nakai","year":"2016","unstructured":"Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T (2016) The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet 41:139\u2013147","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5127_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.2042-7158.1985.tb03035.x","volume":"37","author":"RP Gural","year":"1985","unstructured":"Gural RP, Chungi VS, Shrewsbury RP, Dittert LW (1985) Dose-dependent absorption of disodium etidronate. J Pharm Pharmacol 37:443\u2013445","journal-title":"J Pharm Pharmacol"},{"key":"5127_CR30","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00198-015-3175-1","volume":"26","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Ito M, Hashimoto J et al (2015) Clinical efficacy and safety of monthly oral ibandronate 100\u00a0mg versus monthly intravenous ibandronate 1\u00a0mg in Japanese patients with primary osteoporosis. Osteoporos Int 26:2685\u20132693","journal-title":"Osteoporos Int"},{"key":"5127_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00535-005-1672-2","volume":"40","author":"A Muramatsu","year":"2005","unstructured":"Muramatsu A, Azuma T, Okuda T, Satomi S, Ohtani M, Lee S, Suto H, Ito Y, Yamazaki Y, Kuriyama M (2005) Association between interleukin-1beta-511C\/T polymorphism and reflux esophagitis in Japan. J Gastroenterol 40:873\u2013877","journal-title":"J Gastroenterol"},{"key":"5127_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1248\/bpb.24.313","volume":"24","author":"M Morihara","year":"2001","unstructured":"Morihara M, Aoyagi N, Kaniwa N, Kojima S, Ogata H (2001) Assessment of gastric acidity of Japanese subjects over the last 15\u00a0years. Biol Pharm Bull 24:313\u2013315","journal-title":"Biol Pharm Bull"},{"key":"5127_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5414\/CPP44655","volume":"44","author":"G Pillai","year":"2006","unstructured":"Pillai G, Gieschke R, Goggin T, Barrett J, Worth E, Steimer JL (2006) Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int J Clin Pharmacol Ther 44:655\u2013667","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05127-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T23:33:44Z","timestamp":1603323224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5127"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05127-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"19 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was authorized and supported by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). The views and conclusions contained herein are those of the authors and do not represent those of F. Hoffmann-La Roche Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}